Cytotoxicity of paclitaxel in comparison with other anticancer agents against neoplastic cells obtained from clinical gastrointestinal carcinoma tissue.
We examined the activity of paclitaxel against primary cultured cells from gastrointestinal neoplasmas, such as stomach, colon, hepatocellular and pancreatic cancer, and estimated the clinical use of paclitaxel. Antitumor activity, expressed as reduction in cell survival rates mediated by anticancer agents, was measured using [3H]thymidine incorporation into primary cell cultured. Percent survival rates for stomach, colon and hepatocellular cancer cells in the presence of 0.5 microM paclitaxel were 68.1%, 58.4% and 65.1%, respectively. Proportions of gastrointestinal cancer cases having percent survival rates of < or = 70% for paclitaxel, CDDP, MMC and ADM were 48.3%, 17.4%, 28.0% and 21.1%, respectively. The rate for paclitaxel was the highest of all. The proportion of stomach, colon, liver and pancreatic cancer cases having a percent survival rate of < or = 70% in the percentage of paclitaxel were 55.6%, 66.7%, 50.0% and 20.0%, respectively. In particular, the proportions of stomach and colonal cases having survival rates of < or = 70% for paclitaxel in spite of having survival rates of > 70% for other anticancer drugs were 75% (3/4) and 50% (2/4), respectively. From these results, it is probable that paclitaxel will demonstrate clinical activity in gastrointestinal tract cancers, such as stomach, colon, hepatocellular and pancreatic cancer.